Franklin Resources, Inc. (NYSE: BEN), Oil States International, Inc. (NYSE: OIS), Rex Energy (NASDAQ: REXX), SuccessFactors, Inc. (NASDAQ: SFSF), Rowan Companies, Inc. (NYSE: RDC) and Amedisys, Inc. (NASDAQ: AMED) price targets adjusted by analysts.
Franklin Resources, Inc. (BEN) had its price target raised by Barclays Capital to $166.00. They have an “Overweight” rating on the company.
Oil States International, Inc. (OIS) had its price target raised by Global Hunter Securities from $97.00 to $109.00. They have a “Buy” rating on the company.
Rex Energy (REXX) had its price target raised by Rodman & Renshaw from $16.00 to $20.00. They have an “Outperform” rating on the company.
SuccessFactors, Inc. (SFSF) had its price target slashed by BMO Capital Markets from $43.00 to $35.00. They have an “Outperform” rating on the company.
Rowan Companies, Inc. (RDC) had its price target raised by Barclays Capital to $49.00. They have an “Overweight” rating on the company.
Amedisys, Inc. (AMED) had its price target lowered by FBR Capital from $35.00 to $22.00. They have a “Market Perform” rating on the company.
Showing posts with label Amedisys. Show all posts
Showing posts with label Amedisys. Show all posts
Thursday, August 4, 2011
Wednesday, January 19, 2011
Amedisys (NASDAQ:AMED) Faces Home Health Pressures
While Amedisys (NASDAQ:AMED) has a growing hospice business, the overall condition of the home health sector is under pressure on the lowering of Medicare pricing in 2011.
FBR says, "Amedisys is in the midst of realigning its resources to fit the needs of the market. But the company remains a market leader in the home health industry, with a growing hospice presence. The home health marketplace remains a challenge as Medicare pricing was cut for 2011 and could see a modest reduction in 2012. Amedisys, like its peers, must face the potential of rebasing in 2014 as well as wait for resolution of the pending investigations. We believe that regardless of the outcome of those investigations, the entire industry should expect to see a greater level of regulatory scrutiny. These factors remain overhangs on the industry and AMED shares."
FBR Capital reiterates a "Market Perform" rating on Amedisys (AMED), which closed Tuesday at $32.35, losing $0.89, or 2.68 percent. FBR raised their price target on Amedisys from $27 to $31.
FBR says, "Amedisys is in the midst of realigning its resources to fit the needs of the market. But the company remains a market leader in the home health industry, with a growing hospice presence. The home health marketplace remains a challenge as Medicare pricing was cut for 2011 and could see a modest reduction in 2012. Amedisys, like its peers, must face the potential of rebasing in 2014 as well as wait for resolution of the pending investigations. We believe that regardless of the outcome of those investigations, the entire industry should expect to see a greater level of regulatory scrutiny. These factors remain overhangs on the industry and AMED shares."
FBR Capital reiterates a "Market Perform" rating on Amedisys (AMED), which closed Tuesday at $32.35, losing $0.89, or 2.68 percent. FBR raised their price target on Amedisys from $27 to $31.
Subscribe to:
Posts (Atom)